Yuanyuan Hao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuanyuan Hao has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Mingye Wang
College of Integrated Chinese and Western Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050035, China
3 shared publications - Yunlong Hou
National Key Laboratory for Innovation and Transformation of Luobing Theory, Shijiazhuang 050035, China
3 shared publications - Wenwen Cui
College of Integrated Chinese and Western Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050035, China
2 shared publications - Aiqun Ma
Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
1 shared publication Bing Yao
National Key Laboratory of Collateral Disease Research and Innovative Chinese Medicine
1 shared publicationChi Zhao
Hebei Medical University, No. 361, East Zhongshan Road, Shijiazhuang, Hebei 050017, China
1 shared publication
Latest Publications
- Open Access
- 31 January 2023
- Published by Elsevier in Phytomedicine
- Vol. 112, 154688
Sophoridine manifests as a leading compound for anti-arrhythmia with multiple ion-channel blocking effects
- 31 January 2023
- Published by Elsevier in Phytomedicine
- Vol. 112, 154688
Open AccessSophoridine manifests as a leading compound for anti-arrhythmia with multiple ion-channel blocking effects
- 8 August 2022
- Published by American Psychological Association (APA)
Social Anxiety Scale for Social Media Users--Chinese Version
- 8 August 2022
- Published by American Psychological Association (APA)
Social Anxiety Scale for Social Media Users--Chinese Version
- Open Access
- 9 February 2022
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 60 (1) , 274-281
Jinlida granules ameliorate the high-fat-diet induced liver injury in mice by antagonising hepatocytes pyroptosis
Jinlida (JLD) as a traditional Chinese medicine formula has been used to treat type 2 diabetes mellitus (T2DM) and studies have shown its anti-obesity effect.To investigate the therapeutic effects ...
- 9 February 2022
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 60 (1) , 274-281
Open AccessJinlida granules ameliorate the high-fat-diet induced liver injury in mice by antagonising hepatocytes pyroptosis
Jinlida (JLD) as a traditional Chinese medicine formula has been used to treat type 2 diabetes mellitus (T2DM) and studies have shown its anti-obesity effect.To investigate the therapeutic effects ...
- Open Access
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 4483009
Jinlida Granules Reduce Obesity in db/db Mice by Activating Beige Adipocytes
Recent studies indicate existence of beige adipocytes in adults. Upon activation, beige adipocytes burn energy for thermogenesis and contribute to regulation of energy balance. In this study, we have analyzed whether Jinlida granules (JLD) could activate beige adipocytes. JLD suspended in 0.5% carboxymethyl cellulose (CMC) was gavage fed to db/db mice at a daily dose of 3.8 g/kg. After 10 weeks, body weight, biochemical, and histological analyses were performed. In situ hybridization, immunofluorescence, and western blotting were conducted to test beige adipocyte activation in mice. X9 cells were induced with induction medium and maintenance medium containing 400 μg/mL of JLD. After completion of induction, cells were analyzed by Nile red staining, time polymerase chain reaction (PCR), western blotting, and immunofluorescence to understand the effect of JLD on the activation of beige adipocytes. A molecular docking method was used to preliminarily identify compounds in JLD, which hold the potential activation effect on uncoupling protein 1 (UCP1). JLD treatment significantly improved obesity in db/db mice. Biochemical results showed that JLD reduced blood glucose (GLU), triglyceride (TG), and low‐density lipoprotein cholesterol (LDL) levels as well as liver aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels in mice. Hematoxylin and eosin staining (H&E) showed that JLD reduced hepatocyte ballooning changes in the liver. Immunofluorescence showed that JLD increased the expression of the thermogenic protein, UCP1, in the beige adipose tissue of mice. JLD also increased the expression of UCP1 and inhibited the expression of miR‐27a in X9 cells. Molecular docking results showed that epmedin B, epmedin C, icariin, puerarin, and salvianolic acid B had potential activation effects on UCP1. The results suggest that JLD may activate beige adipocytes by inhibiting miR‐27a expression, thereby promoting thermogenesis in beige adipocytes. This study provides a new pharmacological basis for the clinical use of JLD.
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 4483009
Open AccessJinlida Granules Reduce Obesity in db/db Mice by Activating Beige Adipocytes
Recent studies indicate existence of beige adipocytes in adults. Upon activation, beige adipocytes burn energy for thermogenesis and contribute to regulation of energy balance. In this study, we have analyzed whether Jinlida granules (JLD) could activate beige adipocytes. JLD suspended in 0.5% carboxymethyl cellulose (CMC) was gavage fed to db/db mice at a daily dose of 3.8 g/kg. After 10 weeks, body weight, biochemical, and histological analyses were performed. In situ hybridization, immunofluorescence, and western blotting were conducted to test beige adipocyte activation in mice. X9 cells were induced with induction medium and maintenance medium containing 400 μg/mL of JLD. After completion of induction, cells were analyzed by Nile red staining, time polymerase chain reaction (PCR), western blotting, and immunofluorescence to understand the effect of JLD on the activation of beige adipocytes. A molecular docking method was used to preliminarily identify compounds in JLD, which hold the potential activation effect on uncoupling protein 1 (UCP1). JLD treatment significantly improved obesity in db/db mice. Biochemical results showed that JLD reduced blood glucose (GLU), triglyceride (TG), and low‐density lipoprotein cholesterol (LDL) levels as well as liver aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels in mice. Hematoxylin and eosin staining (H&E) showed that JLD reduced hepatocyte ballooning changes in the liver. Immunofluorescence showed that JLD increased the expression of the thermogenic protein, UCP1, in the beige adipose tissue of mice. JLD also increased the expression of UCP1 and inhibited the expression of miR‐27a in X9 cells. Molecular docking results showed that epmedin B, epmedin C, icariin, puerarin, and salvianolic acid B had potential activation effects on UCP1. The results suggest that JLD may activate beige adipocytes by inhibiting miR‐27a expression, thereby promoting thermogenesis in beige adipocytes. This study provides a new pharmacological basis for the clinical use of JLD.
- Open Access
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 7013299
Inhibition of Autophagy Facilitates XY03‐EA‐Mediated Neuroprotection against the Cerebral Ischemia/Reperfusion Injury in Rats
Objective. L‐3‐n‐Butylphthalide (NBP) is used to treat moderate and severe acute ischemia stroke. A previous screening study indicates that XY03‐EA, a novel derivative of NBP, is more potent than NBP in the oxyradical scavenging capacity. In this study, in vivo and in vitro ischemia/reperfusion (I/R) models were used to test whether the XY03‐EA offered therapeutic benefits in the ischemic stroke and explore the underlying mechanism of action. Methods. For this purpose, behavioral scores, cerebral infarct volume, cerebral blood flow, oxidative stress levels, inflammatory factor expression, energy metabolism levels, and autophagy activation were estimated in the rat middle cerebral artery occlusion and reperfusion (MCAO/R) model. The nonhuman primate MCAO/R model was conducted to validate the therapeutic effect of XY03‐EA applied for 3 weeks. The neurological deficit score (NDS) progression rate and the infarct volume were continuously recorded on days 3, 7, 14, and 21. The PC‐12 cell OGD/R model was used to assess the cell survival rate, reactive oxygen species (ROS) levels, the expression of autophagy execution molecules, and the activation of autophagy‐related signaling pathways. Results. XY03‐EA decreased the cerebral injuries and NDS by increasing cerebral blood flow, improving brain energy metabolism, accelerating ROS clearance, suppressing inflammatory responses, and inhibiting autophagy in the MCAO/R model rats. In the nonhuman primate MCAO/R model, the treatment of XY03‐EA for 3 weeks could significantly inhibit the NDS progression rate and indicate a positive trend to reduce the infarct volume in a dose‐dependent way. Mechanistically, XY03‐EA inhibited ROS‐dependent autophagy activation and thereby protected the PC‐12 cells from the autophagic cell death induced by OGD/R. Conclusions. In this study, we found that XY03‐EA alleviated the cerebral I/R injuries in rats and nonhuman primates. Our results demonstrated that XY03‐EA exerted neuroprotective effects against the ROS‐mediated autophagic neurocyte death and had great potential for the treatment of ischemic stroke.
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 7013299
Open AccessInhibition of Autophagy Facilitates XY03‐EA‐Mediated Neuroprotection against the Cerebral Ischemia/Reperfusion Injury in Rats
Objective. L‐3‐n‐Butylphthalide (NBP) is used to treat moderate and severe acute ischemia stroke. A previous screening study indicates that XY03‐EA, a novel derivative of NBP, is more potent than NBP in the oxyradical scavenging capacity. In this study, in vivo and in vitro ischemia/reperfusion (I/R) models were used to test whether the XY03‐EA offered therapeutic benefits in the ischemic stroke and explore the underlying mechanism of action. Methods. For this purpose, behavioral scores, cerebral infarct volume, cerebral blood flow, oxidative stress levels, inflammatory factor expression, energy metabolism levels, and autophagy activation were estimated in the rat middle cerebral artery occlusion and reperfusion (MCAO/R) model. The nonhuman primate MCAO/R model was conducted to validate the therapeutic effect of XY03‐EA applied for 3 weeks. The neurological deficit score (NDS) progression rate and the infarct volume were continuously recorded on days 3, 7, 14, and 21. The PC‐12 cell OGD/R model was used to assess the cell survival rate, reactive oxygen species (ROS) levels, the expression of autophagy execution molecules, and the activation of autophagy‐related signaling pathways. Results. XY03‐EA decreased the cerebral injuries and NDS by increasing cerebral blood flow, improving brain energy metabolism, accelerating ROS clearance, suppressing inflammatory responses, and inhibiting autophagy in the MCAO/R model rats. In the nonhuman primate MCAO/R model, the treatment of XY03‐EA for 3 weeks could significantly inhibit the NDS progression rate and indicate a positive trend to reduce the infarct volume in a dose‐dependent way. Mechanistically, XY03‐EA inhibited ROS‐dependent autophagy activation and thereby protected the PC‐12 cells from the autophagic cell death induced by OGD/R. Conclusions. In this study, we found that XY03‐EA alleviated the cerebral I/R injuries in rats and nonhuman primates. Our results demonstrated that XY03‐EA exerted neuroprotective effects against the ROS‐mediated autophagic neurocyte death and had great potential for the treatment of ischemic stroke.
- 1 October 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 479 (4) , 833-840
Lin28a protects against postinfarction myocardial remodeling and dysfunction through Sirt1 activation and autophagy enhancement
- 1 October 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 479 (4) , 833-840
Lin28a protects against postinfarction myocardial remodeling and dysfunction through Sirt1 activation and autophagy enhancement